Analysis identifies key manufacturers in the ADC payload market
Roots Analysis provides a market overview of major manufacturers producing cytotoxic payloads for antibody-drug conjugates (ADCs).
Market research firm Roots Analysis has released a study detailing the competitive landscape of antibody-drug conjugate (ADC) payload manufacturing. As targeted cancer therapies gain traction, with significant approvals in 2025 for drugs such as Telisotuzumab vedotin and Trastuzumab rezetecan, the demand for specialized cytotoxic warhead production has intensified.
The effectiveness of ADCs relies on the potency and stability of their cytotoxic components. While traditional DNA-damaging agents and tubulin inhibitors remain standard, the industry is increasingly exploring topoisomerase inhibitors to enhance therapeutic indexes. These technical improvements are driving the next phase of market growth for specialized contract manufacturing organizations (CMOs).
The report highlights six prominent manufacturers currently leading the supply chain: CARBOGEN AMCIS, Cerbios-Pharma, Levena Biopharma, MabPlex, MilliporeSigma (Merck), and WuXi STA. These entities support drug developers through various stages, from preclinical research to large-scale commercial manufacturing.
Industry consolidation and strategic partnerships remain a primary trend. Companies are increasingly moving toward end-to-end development models to streamline the integration of biologics and chemical payloads, a shift exemplified by the recent collaboration between CARBOGEN AMCIS and Celonic.